Form 8-K - Current report:
SEC Accession No. 0001213900-25-062859
Filing Date
2025-07-10
Accepted
2025-07-10 17:12:55
Documents
14
Period of Report
2025-07-10
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0248604-8k_klotho.htm   iXBRL 8-K 30338
2 PRESS RELEASE ea024860401ex99-1_klotho.htm EX-99.1 10125
  Complete submission text file 0001213900-25-062859.txt   255446

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE klto-20250710.xsd EX-101.SCH 3496
4 XBRL DEFINITION FILE klto-20250710_def.xml EX-101.DEF 26515
5 XBRL LABEL FILE klto-20250710_lab.xml EX-101.LAB 36423
6 XBRL PRESENTATION FILE klto-20250710_pre.xml EX-101.PRE 25139
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0248604-8k_klotho_htm.xml XML 5482
Mailing Address 13576 WALNUT STREET, SUITE A OMAHA NE 68144
Business Address 13576 WALNUT STREET, SUITE A OMAHA NE 68144 (833) 931-6330
Klotho Neurosciences, Inc. (Filer) CIK: 0001907223 (see all company filings)

EIN.: 862727441 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41340 | Film No.: 251116969
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)